p53 autoantibodies, cytokine levels and ovarian carcinogenesis
- 31 July 2009
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 114 (1) , 12-17
- https://doi.org/10.1016/j.ygyno.2009.03.028
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical ImpactJournal of Clinical Oncology, 2008
- Generation and regulation of human CD4 + IL-17-producing T cells in ovarian cancerProceedings of the National Academy of Sciences, 2008
- A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutationsGynecologic Oncology, 2008
- Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesisAmerican Journal of Obstetrics and Gynecology, 2008
- The impact of T‐cell immunity on ovarian cancer outcomesImmunological Reviews, 2008
- Antigen‐specific immunotherapy of cervical and ovarian cancerImmunological Reviews, 2008
- Pathogenesis of Ovarian CancerInternational Journal of Gynecological Pathology, 2008
- Autoantibodies in breast cancer: their use as an aid to early diagnosisAnnals of Oncology, 2007
- Assessment of the Prognostic Relevance of Serum Anti-p53 Antibodies in Epithelial Ovarian CancerGynecologic Oncology, 1999
- p53, guardian of the genomeNature, 1992